Asia Pacific Respiratory Inhalers Market Report and Forecast 2024-2032

The global respiratory inhalers market size was valued at USD 33.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. It is expected to grow at a CAGR of 6.4% during the forecast period of 2024-2032, with the values likely to attain USD 53.9 billion by 2032.

Key Takeaways

• Recent data reveals that China accounts for nearly 25% of all COPD cases globally, with around 100 million living with this chronic lung condition . The rising burden of respiratory conditions is expected to fuel market demand.
• In August 2023, AstraZeneca revealed its plan to invest an additional amount of USD 250 million in its asthma inhaler plant in China’s Qingdao, with the total investment in the factory reported to be USD 700 million. Such substantial investments to address the medical needs of the rising patient pool are expected to elevate the Asia Pacific respiratory inhalers market value.
• The market is also influenced by the increased initiatives and campaigns to raise awareness about respiratory diseases and their management. In May 2023, Alkem Laboratories Limited announced its 'Reliever Free India' initiative to raise awareness about asthma and the hazards of over-usage of reliever medication.

Asia Pacific Respiratory Inhalers Market Analysis

Respiratory inhalers are medical devices that are employed to deliver medication directly to the lungs of patients suffering from respiratory disorders. There is a growing trend towards the adoption of digitally operated and smart inhaler technologies in the market. Smart inhalers are known to facilitate effective disease management by monitoring and providing feedback on the patient's usage patterns. Thus, the Asia Pacific respiratory inhalers market growth is significantly influenced by the technological advancements in inhaler devices.

The market is also impacted by the rising burden of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension in the Asia Pacific region. Recent data reveals that China accounts for nearly 25% of all COPD cases globally, with around 100 million living with this chronic lung condition . Moreover, it is estimated that with the rising smoking rates and an aging population, the prevalence rate of COPD is likely to increase in the coming 40 years. Consequently, the market demand for respiratory inhalers is poised to witness a surge in the forecast period.

One of the major Asia Pacific respiratory inhalers market trends is the increased investment in the respiratory inhaler segment by key market players with the aim to improve access to innovative drugs and accommodate the growing healthcare demands. In August 2023, AstraZeneca announced its plan to invest an additional amount of USD 250 million in its asthma inhaler plant in China’s Qingdao, with the total investment in the factory reported to be USD 700 million. By collaborating with the Qingdao municipal government, the firm intends to manufacture its Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate inhalers for chronic obstructive pulmonary diseases such as asthma. Such substantial investments to address the medical needs of the rising patient pool are expected to elevate the market value.

The increased initiatives and campaigns to raise awareness about respiratory diseases and their management are poised to positively influence the Asia Pacific respiratory inhalers market share. For instance, in May 2023, an Indian multinational pharmaceutical company Alkem Laboratories Limited announced its 'Reliever Free India' initiative to raise awareness about asthma and the hazards of over-usage of reliever medication. The campaign promotes the use of SMART therapy which requires only one inhaler for daily and reliever asthma treatment. The rise of such initiatives coupled with the increasing healthcare expenditure in the region is expected to bolster market growth.

Asia Pacific Respiratory Inhalers Market Segmentation

Market Breakup by Product Type

• Dry Powdered Inhalers
• Multi-Dose Dry Powder Inhalers
• Single Dose Dry Powder Inhalers
• Metered Dose Inhalers
• Pressured Metered Dose Inhalers
• Connected Metered Dose Inhalers
• Nebulizers
• Compressed Air Nebulizers
• Mesh Air Nebulizers
• Ultrasonic Air Nebulizers

Market Breakup by Technology

• Manually Operated Inhaler
• Digitally Operated Inhaler

Market Breakup by Indication

• Asthma
• COPD
• Pulmonary Arterial Hypertension
• Other Respiratory Diseases

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by End Use

• Hospitals and Clinics
• Homecare Settings
• Respiratory Care Centres

Market Breakup by Countries

• China
• Japan
• ASEAN
• Australia
• India
• Others

Asia Pacific Respiratory Inhalers Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• AstraZeneca Plc
• Beximco Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• Cipla Ltd
• GSK Plc
• Koninklijke Philips NV
• OMRON Corp
• PARI Respiratory Equipment, Inc.
• OPKO Health, Inc
• Teva Pharmaceutical Industries Ltd

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Asia Pacific respiratory inhalers market forecast outlook for 2024-2032?
The Asia Pacific respiratory inhalers market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 53.9 billion by 2032.

What are the major factors aiding the Asia Pacific respiratory inhalers market demand?
The rising demand for digitally operated and smart inhaler technologies is fuelling the demand for the market.

What are the major Asia Pacific respiratory inhalers market trends?
One of the significant trends in the market is the increased investment in the respiratory inhaler segment by the key market players. In August 2023, AstraZeneca invested an additional amount of USD 250 million in its asthma inhaler plant in China’s Qingdao, with the total investment in the factory reported to be USD 700 million.

What is the market segmentation based on the product type?
Based on the product type, the market is segmented into dry powdered inhalers (multi-dose dry powder inhalers, single dose dry powder inhalers), metered dose inhalers (pressured metered dose inhalers, connected metered dose inhalers), and nebulizers (compressed air nebulizers, mesh air nebulizers, ultrasonic air nebulizers), among others.

What is the market breakup by technology?
By technology, the market is divided into manually operated inhalers and digitally operated inhalers.

What is the market breakup by indication?
By indication, the market includes asthma, COPD, and pulmonary arterial hypertension, among other respiratory diseases.

What is the market breakup by end user?
By end use, the market is segmented into hospitals & clinics, homecare settings, and respiratory care centers.

What are the distribution channels of the market?
Major distribution channels of the market include hospital pharmacies, retail pharmacies and online pharmacies.

What is the market segmentation by countries?
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.

Who are the key players involved in the Asia Pacific respiratory inhalers market?
The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc., OPKO Health, Inc., and Teva Pharmaceutical Industries Ltd.


This product will be delivered within 5-7 business days.